Rein Therapeutics (NASDAQ:RNTX) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Rein Therapeutics (NASDAQ:RNTX – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.04, FiscalAI reports.

Rein Therapeutics Stock Down 27.5%

NASDAQ:RNTX opened at $0.40 on Tuesday. Rein Therapeutics has a one year low of $0.28 and a one year high of $2.10. The stock has a 50 day moving average price of $0.70 and a 200 day moving average price of $1.00.

Hedge Funds Weigh In On Rein Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RNTX. Chicago Partners Investment Group LLC increased its stake in shares of Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after acquiring an additional 10,000 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Rein Therapeutics during the 3rd quarter valued at about $127,000. Rock Creek Group LLC boosted its position in shares of Rein Therapeutics by 40.0% during the 3rd quarter. Rock Creek Group LLC now owns 175,000 shares of the company’s stock valued at $141,000 after acquiring an additional 50,000 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new position in shares of Rein Therapeutics during the 2nd quarter valued at about $260,000. Finally, Sigma Planning Corp grew its holdings in shares of Rein Therapeutics by 41.0% in the first quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock valued at $453,000 after purchasing an additional 101,400 shares during the period. Institutional investors and hedge funds own 90.89% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on RNTX. HC Wainwright reaffirmed a “buy” rating on shares of Rein Therapeutics in a research note on Tuesday, August 18th. Weiss Ratings lowered shares of Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. Finally, Maxim Group initiated coverage on shares of Rein Therapeutics in a research note on Monday, July 20th. They set a “buy” rating and a $4.00 price objective for the company. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $6.00.

View Our Latest Research Report on RNTX

About Rein Therapeutics

(Get Free Report)

Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious pulmonary and fibrotic diseases. Its research focuses on therapies intended to address disease processes involved in lung injury and fibrosis. The company’s pipeline includes LTI-03, an investigational candidate being developed for idiopathic pulmonary fibrosis, and LTI-01, a candidate studied for loculated pleural effusions. These programs are investigational; they are not approved treatments.

Read More

Earnings History for Rein Therapeutics (NASDAQ:RNTX)

Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.